An investor piece arguing that three of Lilly's pipeline drugs, not Zepbound, could drive the stock's next move. The drugs are named in the full story.
Recap by typeshit. Full story at The Globe and Mail.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
11:54
Ryan Sims of Optimal Health Project gives a follow-up on how things have gone in the months since his 35-pound loss on the experimental drug.
The Tico Times reports Costa Rica's public system is considering offering GLP-1 weight loss drugs to patients. Tap through for where the discussion stands.
Investseekers points to Fierce Pharma's refreshed chart showing how the two oral obesity pill launches from Novo Nordisk and Eli Lilly are tracking over time.
ETFDb lists the REX Peptide ETF among this week's new funds. It targets companies working on peptide drugs, supplements, cosmetics and devices.
Loading…